Psoriatic arthritis (PsA) is a chronic inflammatory disease that can lead to irreversible joint damage and functional impairment. While several biologic therapies effectively manage symptoms, the ability to inhibit structural damage progression is a critical differentiator. Guselkumab, an interleukin-23 (IL-23) inhibitor, has now received an updated label to include this specific indication.
Psoriatic arthritis (PsA) is a heterogeneous inflammatory condition affecting joints, entheses, and skin, often leading to progressive structural damage if not adequately controlled. The primary goal of PsA treatment extends beyond symptom management to include the prevention of irreversible joint destruction. Biologic disease-modifying antirheumatic drugs (bDMARDs) have demonstrated efficacy in various PsA domains, but specific evidence for structural damage inhibition is a key consideration for long-term patient outcomes.
The Evidence for Structural Damage Inhibition
The updated label for guselkumab (Tremfya), an IL-23 inhibitor, is based on data from the DISCOVER-1 and DISCOVER-2 Phase 3 clinical trials. These trials evaluated the efficacy and safety of guselkumab in adult patients with active psoriatic arthritis.1
The DISCOVER-2 trial, in particular, focused on patients who were biologic-naïve. In this study, guselkumab demonstrated significant inhibition of radiographic progression at week 24 compared to placebo. Radiographic progression was assessed using the modified Total Sharp Score (mTSS), which evaluates joint erosion and joint space narrowing in the hands and feet.1
At week 24, patients receiving guselkumab 100 mg every four weeks (Q4W) showed a mean change from baseline in mTSS of 0.04, while those receiving guselkumab 100 mg every eight weeks (Q8W) showed a mean change of 0.07. In contrast, the placebo group demonstrated a mean change of 0.80. The difference between both guselkumab groups and placebo was statistically significant (p < 0.001 for both).1
A higher proportion of guselkumab-treated patients achieved no radiographic progression (defined as an mTSS change from baseline of ≤0.5) compared to placebo. Specifically, 82% of patients in the Q4W group and 76% in the Q8W group achieved no radiographic progression, versus 53% in the placebo group.1
The DISCOVER-1 trial, which included patients previously treated with anti-tumour necrosis factor (TNF) alpha agents, also provided supportive data. While the primary endpoint for structural damage was not met in DISCOVER-1 due to a lower baseline rate of progression in the placebo group, numerical trends consistent with inhibition of structural damage were observed.2
Across both studies, the safety profile of guselkumab was consistent with previous reports for psoriasis, with common adverse events including upper respiratory tract infections, headache, and injection site reactions. No new safety signals emerged during the trials.1,2
The inclusion of structural damage inhibition in the label provides clinicians with additional evidence when selecting a biologic therapy for PsA. This specific claim differentiates guselkumab within the crowded PsA treatment landscape, particularly for patients where preventing long-term joint destruction is a paramount concern. The data from DISCOVER-2, focusing on biologic-naïve patients, is particularly relevant for initial treatment decisions.
The updated label for guselkumab to include inhibition of structural damage progression in psoriatic arthritis is a welcome clarification, not a revolution. For years, clinicians have understood that effective disease control in PsA, particularly with biologics, correlates with reduced radiographic progression. However, having this explicit claim on the label, backed by robust Phase 3 data from the DISCOVER-2 trial, provides a firmer evidence base for treatment selection, especially when discussing long-term outcomes with patients.
This development will likely influence prescribing patterns, particularly for rheumatologists prioritising joint preservation in newly diagnosed or biologic-naïve PsA patients. While other biologics, including TNF inhibitors and IL-17 inhibitors, have also demonstrated structural benefits, guselkumab's specific mechanism of action (IL-23 inhibition) offers an alternative for patients who may not respond to or tolerate other classes. It also provides Janssen with a distinct marketing advantage in a competitive market, allowing them to highlight a specific, measurable benefit beyond symptomatic relief.
For patients, this means more precise information regarding the potential for their chosen therapy to protect their joints from irreversible damage. It underscores the importance of early and effective treatment in PsA. However, it also places a greater onus on clinicians to clearly articulate the nuances of structural damage inhibition across different biologic classes, ensuring that treatment decisions are truly individualised and not solely driven by a single label claim. The ultimate goal remains comprehensive disease control, encompassing skin, joints, entheses, and dactylitis, alongside the critical objective of preventing long-term disability.
- The Pivot Guselkumab's label now explicitly includes inhibition of structural damage progression in psoriatic arthritis.
- The Data Radiographic progression, measured by the modified Total Sharp Score (mTSS), was significantly inhibited in guselkumab-treated patients versus placebo.
- The Action Clinicians should consider guselkumab for PsA patients where inhibition of structural damage is a primary treatment goal.
ART-2026-195
Cite This Article
Team TLSFE. Guselkumab label adds psoriatic arthritis structural damage inhibition. The Life Science Feed. Updated May 31, 2026. Accessed May 31, 2026. https://thelifesciencefeed.com/rheumatology/arthritis-psoriatic/news/guselkumab-label-adds-psoriatic-arthritis-structural-damage-inhibition.
Licence & Rights
© 2026 The Life Science Feed. All rights reserved. Unless otherwise indicated, all content is the property of The Life Science Feed and may not be reproduced, distributed, or transmitted in any form or by any means without prior written permission.
Editorial & AI Standards
All content is researched from peer-reviewed, open-access sources — published trial data, clinical guidelines, and regulatory filings. AI tools are used solely to structure and summarise that evidence; no AI-generated conclusions appear without editor verification against the primary source.
Every article is reviewed by a named editor before publication. Source citations are listed in the References section. This content does not represent the views of any pharmaceutical company, medical device manufacturer, or healthcare provider.
References
1. Deodhar A, et al. Guselkumab in biologic-naïve patients with active psoriatic arthritis: a phase 3, multicentre, double-blind, placebo-controlled study (DISCOVER-2). Lancet. 2020;395(10230):1115-1126.
2. Ritchlin CT, et al. Guselkumab in patients with active psoriatic arthritis who were previously treated with tumour necrosis factor inhibitors: a phase 3, multicentre, double-blind, placebo-controlled study (DISCOVER-1). Lancet. 2020;395(10230):1127-1136.
